Schrödinger Q3 revenue $29.9M (+16% YoY); net loss $35M vs $3.9M income; lowers drug discovery revenue guidance

Schrodinger, Inc.

2021-Q3 EPS reported -$0.99 revenue$91,761,000

Revenue $29.9M (+16% YoY); software revenue $24.3M (+6%), drug discovery $5.6M (up from $2.9M).
Net loss $35.0M vs net income $3.9M in Q3 2020; operating expenses rose to $45.8M from $30.7M.
Cash and marketable securities $600.2M as of Sep 30, 2021, down from $616.6M at Jun 30.
Full-year drug discovery revenue guidance revised to $22-24M from $22-32M; software guidance maintained at $102-110M.
Selected development candidate for CDC7 inhibitor; MALT1 IND submission expected H1 2022; pipeline expanded to five programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.